Replies to post #143107 on Biotech Values

[mcbio]

I am still debating on ECYT. Value wise compelling for small molecule conjugate, but no survival trend for randomized trial bothers me.

ECYT has disclosed they don't need to show OS benefit for accelerated approval, just strong PFS benefit.

I would not take a gamble on BIOD. If you already have a position, then it might be different.

BIOD is clearly highly speculative but I am going to keep holding on my position. They have cash till mid-2013 and I thought the P1 data on the two new URA insulins was positive. And we should have P1 results for the two analogs in 1Q13. One of the big risks, of course, is if the stock doesn't move much in the next 6-9 months, and they don't otherwise ink a partnership, they will be in no position to raise capital. So, clearly a big risk. On the flip side, market cap just ~$30M and if they ever do ink a lucrative deal, I would think there is potential for nice upside.